Cox regression for NT-proBNP percentage reduction during hospitalisation and 6-month all-cause mortality
| HFpEF (EF ≥50%) | HFrEF (EF <40%) | |||
| Univariable model HR (95% CI) | Multivariable model* HR (95% CI) | Univariable model HR (95% CI) | Multivariable model* HR (95% CI) | |
| NT-proBNP reduction during hospitalisation | ||||
| >60% | 1 | 1 | 1 | 1 |
| 30%–60% | 3.35 (1.11 to 10.11) | 3.28 (1.07 to 10.12) | 2.23 (1.23 to 4.04) | 1.79 (0.99 to 3.26) |
| ≤30% | 5.01 (1.62 to 15.55) | 4.60 (1.47 to 14.40) | 5.12 (3.00 to 8.73) | 3.36 (1.93 to 5.85) |
| Cox regression for NT-proBNP percentage reduction during hospitalisation and the composite endpoint of 6-month cardiovascular readmission/all-cause mortality | ||||
| NT-proBNP reduction during hospitalisation | ||||
| >60% | 1 | 1 | 1 | 1 |
| 30%–60% | 1.51 (0.91 to 2.49) | 1.41 (0.83 to 2.38) | 1.99 (1.48 to 2.69) | 1.78 (1.32 to 2.42) |
| ≤30% | 1.63 (1.03 to 2.60) | 1.69 (1.06 to 2.71) | 2.77 (2.08 to 3.68) | 2.21 (1.63 to 3.00) |
*Adjusted for age ≥75 years, peripheral oedema, systolic blood pressure ≤115 mm Hg, hyponatraemia (sodium level <135 mmol/L), serum urea ≥15 mmol/L.
EF, ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide.